Friday, 22. 5. 2017    

Cancer Cell Research (Online ISSN: 2161-2609)


Current Issue

Vol.4  No.15


Article: Prrx1 enhanced the migration ability of breast cancer cell by initiating epithelial-mesenchymal Transition
by  Wenjuan Wang, Zhidong Lv, Zhaochuan Yang, Peihong Zhou, Jiaojiao Dong, Funian Li
Cancer Cell Research 2017 4(15) 362-367; published online 27 April 2017
Abstract: To study the effect of paired related homoeobox1 (Prrx1) on the epithelial-mesenchymal transition (EMT) and migration ability of breast cancer cells. Breast cancer cell lines (including BT-474, ZR-75-1 and Mccoy’s 5A) were filtrated by Real-time PCR to obtain the cells with the lowest expression of Prrx1. Then the cells were transfected with Prrx1 over-expression letiviral vectors. Then the phenotype changes of the cells were observed after the infection was verified to be performed through Real-time PCR. The expression of Twist protein was tested by Western blot. At last, the effect of Prrx1 on the migration ability of the breast cancer cell was determined by Transwell assay. Mccoy’s 5A cells were screened to be the lowest Prrx1 expression cells in the three kinds of breast cancer cells. Then the Mccoy’s 5A cells were transfected by letiviral vectors to be Prrx1 over-expressing. We observed that the morphology of these cells changed from polygon to long spindle appearance. The real-time PCR results showed that the expression of Prrx1, E-adherin and Vimentin was 225.80, 0.55, and 4.20 times compared with groups without transfection respectively (p<0.05). Transwell assay showed that the number of the migration cells in over-expression group (72.64±5.32) was higher than both non-treated group (39.52±3.87) and lentiviral vectors group (42.35±4.11) (p<0.05), while the difference between the two control groups were not statistically significant (p>0.05). Prrx1 up-regulation up-regulation can prompt EMT of breast cancer cells and enhance their migration ability.

Open Access Download (free) PDF


Article: Inhibition of HGF- ASODN in Breast Cancer and its influence on cell proliferation
by  Youfeng Guo, Huijuan Hong, Ke Kuang, Zhao Yuan, Jianming Wang
Cancer Cell Research 2017 4(15) 368-373; published online 27 May 2017
Abstract: Oligodeoxynucleotide (ASODN) was synthesized and added to breast cancer MDA-MB-231 cells to see its influence on cell proliferation. After the transfection of HGF ASODN on the MDA-MB-231 cells, immunocytochemical method, western blot and RT-PCR methods were used to test the HGF, VEGF and PCNA level. Cell proliferation was analyzed by MTT method. The results showed that after transfection, 2-8 uM HGF ASODN. It can inhibit expression of HGF and cell proliferation. The inhibition effect begun at 24 hours and lasted to 96 hours. The inhibition effect was related to the concentration. HGF ASODN could also inhibit protein level of VEGF and PCNA. Besides, HGF ASODN in different concentration could also inhibit tumor growth. HGF promoting autocrine and paracrine of IGF-I is important to breast tumor growth.

Open Access Download (free) PDF


Article: Blood supply of viable tumor area of hepatocellular carcinoma after transcatheter arterial chemoembolization
by  Quan Li
Cancer Cell Research 2017 4(15) 374-378; published online 27 May 2017
Abstract: To evaluate the blood supply of viable tumor area (VTA) of hepatocellular carcinoma(HCC)after transcatheter arterial chemoembolization using lipiodol (LP-TACE) by dual-phase multislice computed tomography (MSCT)scanning. Thirty-eight patients with 55 HCCs after LP-TACE treatment were examined by plain scanning and hepatic dual-phase MSCT. The performance of VTA on plain scanning and the enhancement patterns on dynamic contrast-enhanced scanning were observed. In contrast-enhanced CT scans, the blood supply of VTA was classified into four types: arterial blood supply, portal blood supply, arterial together with portal blood supply and poor blood supply. Atthe same time, the attribution of portal venous blood supply to VTA was compared with that before LP-TACE. The VTA appear as a hypoattenuation lesion on unenhanced images, and the CT value of VTA was (37.71±7.78) Hu. In contrast-enhanced CT scans, the blood supply of VTA was classified into four types: arterial blood supply (29 cases), portal blood supply (2 cases), arterial together with portal blood supply (22 cases) and poor blood supply (4 cases). The attribution of portal venous blood supply to VTA was significantly increased after LP-TACE. Arterial blood supply and arterial together with portal blood supply are the two main types of the blood supply with VTA. The attribution of portal venous blood supply to VTA was significantly increased after LP-TACE.

Open Access Download (free) PDF


Article: Liver cirrhosis with chylous hydrothorax and ascites: a case report and literature review
by  Zhengwei Leng, Zhao Yang, Songlin Hou, Xiaoqiong Li, Yunfeng Xiao, 
      Sisi Wang, Lu Yang, Guansheng Huang, Jiali Li, Jinrong Xia, Zhengru Chen, 
      Siyu Li,  Zhonghui Zhou, Jinghuang Chen, Xia qinghua,  Tao kaixiong
Cancer Cell Research 2017 4(15) 378-381; published online 27 May 2017
Abstract: To study the clinical manifestations, pathogenesis, and treatment of liver cirrhosis with chylous hydrothorax and ascites. Methods: A case of liver cirrhosis with chylous hydrothorax and ascites was reported and the related literature was reviewed. Results: The patient was hospitalized due to massive ascites. Paracentesis and a low-fat diet were effective. Diuretics, liver protection-therapy, and somatostatin were performed. Twenty-eight days later, the patient was asymptomatic without recurrent disease at follow-up three months on. Conclusions: Liver cirrhosis with chylous hydrothorax and ascites is rare in clinic patients who have been diagnosed with liver cirrhosis with chylous hydrothorax and ascites exhibits rapid progression and poor prognosis. Low fat and high protein diet should be considered. Diuresis, liver protection-therapy, and the use of somatostatin were performed. The surgery should be performed if necessary.

Open Access Download (free) PDF


 

 
��ҳģ��